Aptahem om bolagets nya forskningsrön
Aptahem publicerade nyligen ett abstract som visar att bolagets läkemedelskandidat Apta-1, som utvecklas som en akutbehandling mot sepsis. Detta abstract sammanfattar den aktuella förståelsen kring effekterna av Apta-1 in vivo. Studierna har identifierat Apta-1 som ett anti-koagulant, en hämmare av hyperinflammatoriskt svar och en inducerare av vävnadsreparation genom signifikant ökade nivåer av Pentraxin-3. BioStock kontaktade Aptahem CSO Luiza Jedlina och Anders Bylock, CMO och ordförande i bolagets vetenskapliga råd, för att få veta mer om resultaten.
Apta-1 är svenska Aptahems primära läkemedelskandidat som utvecklas som ett akutläkemedel mot sepsis, en sjukdom som årligen drabbar 49 miljoner människor varav 11 miljoner dör.
Aptahem har i tidigare studier kunnat påvisa att Apta-1 har en mångfasetterad verkningsprofil. Till skillnad mot dagens behandlingar har forskningen visat att läkemedelskandidaten har antiinflammatoriska, antikoagulerande och immundysfunktions-motverkande effekter. Samtliga dessa är högintressanta egenskaper för en kandidat som skall sättas in för behandling av sepsis. Man har även kunnat visa påtagligt förbättrad överlevnad i vedertagna djurmodeller för sepsis och sepsisliknande sjukdomstillstånd.
Sammantaget innebär dessa fynd att Apta-1 har potential att kunna motverka de skadeverkningar som uppstår när infektioner når blodbanan. Det kan handla om vävnadsnedbrytning, läckande kärl, följt av sänkt blodtryck, samt en livshotande försämring av syresättningen av vitala organ.
Ny studie visar intressanta data
Förra veckan publicerade Aptahem ett abstract som skulle ha presenterats på ISICEM-konferensen i Bryssel, men liksom alla andra fysiska konferenser har denna skjutits fram på grund av den pågående Covid-19-pandemin. I stället för att vänta på ett nytt datum för evenemanget, enades arrangörerna med partnern Critical Care Magazine, en högt rankad tidskrift i kategorin kritisk vård och intensivvårdmedicin, att gå vidare och publicera de nya forskningsresultaten från de godkända bidragen.
Titeln på det publicerade abstractet är “A novel protein-binding RNA aptamer, Apta-1 – a new therapeutic tool to combat sepsis” och huvudförfattare är Aptahems Chief Scientific Officer, Luiza Jedlina.
I studien undersökte forskarteamet Apta-1s in vivo-effekter av behandling på koagulation, inflammation och vävnadsreparation. Dessa tre immunsvar skenar vanligtvis när en individ drabbas av sepsis eller systemiskt inflammatoriskt responssyndrom (SIRS).
Studien genomfördes på icke-humana primater, råttor och möss i etablerade in vivo-modeller för trombos (blodpropp) och endotaxemi (bakterieceller i blodet).
BioStock vände sig till huvudförfattaren själv, Luiza Jedlina, för att få en mer djupgående beskrivning av studien och dess resultat.
Luiza, in the study you have confirmed that Apta-1 has an anti-coagulant effect, can inhibit hyperinflammatory responses of the host immune system and also promote tissue repair. Thus, you conclude that Apta-1 acts on different proteins at the same time. Can you guide us through this?
– It is indeed quite unusual for a drug candidate to display so many in vivo effects. In order to understand the findings, I need to emphasize two features of Apta-1. Firstly, Apta-1 will not enter into the cells, thus avoiding the risk of introducing permanent changes to genetic information.
– Secondly, Apta-1 binds to a specific amino-acid region rather than a specific protein. This amino-acid region can, however,be found on different proteins. These proteins carry multiple functions within host defence mechanisms against infections and inflammation. Some of the proteins extend blood clotting times, hence the observed anti-coagulant effect of Apta-1. Other proteins modulate inflammation from the observed inhibition of hyperinflammatory response by Apta-1. A third group of proteins Apta-1 interferes with involve proteins promoting tissue repair.
»Based on our current knowledge of Apta-1 effects and the recent publications in these fields, we can say that it would be interesting to see if Apta-1 could have a direct or indirect potential against viruses given its multifunctional properties. But our plans right now is to continue to focus on the sepsis effects as our lead candidate Apta-1 is being developed as a treatment of sepsis« — Luiza Jedlina, CSO Aptahem
Mice exposed to bacterial endotoxin were monitored for survival during 72 hours. Mice treated afterwards with Apta-1 reached a survival rate of up to 80 per cent. This can be compared to a 10 per cent survival rate among those who received no treatment. In your opinion, what do these results indicate for potential therapeutic effect of Apta-1 in SIRS and sepsis?
– These are important results indicating a major improvement of survival in systemic inflammatory and potentially also in septic conditions. It becomes even more exciting knowing that the survival rate is Apta-1-dose dependent. To simplify, it indicates that in this model the higher Apta-1 dose applied, the higher survival rate. Altogether, such an improvement in survival rate like the one we observed in this mouse study is seldom seen in this field.
– SIRS as well as sepsis are very complex pathophysiological conditions characterized by dysregulation of several mechanisms in the host immune response. Apta-1 therapeutically targets not only one but three of these mechanisms, i.e. blood coagulation, inflammation and tissue repair. Counteracting all three mechanisms is likely the main reason behind the high survival rate observed in mice. This exact feature makes Apta-1 unique among other candidates.
»It is a very exciting result for any drug candidate to trigger a protein like Pentraxin-3 with such a broad spectrum of effects«
Perhaps the most exciting finding is that you found rapid and significant induction of Pentraxin-3 after Apta-1 treatment. Pentraxin-3 is an acute-phase protein involved in inflammatory and infectious processes. Can you tell us more?
– Before I go into explaining the role of Pentraxin-3, it is important to give some background on how we look at the immune system.
– The immune response has two arms in humans: the adaptive immune response and the innate immune response. The adaptive response is the one people acquire in time through encounters with pathogens in their environment. Adaptive immunity is often represented by pathogen-specific antibodies that develop through the presentation of such pathogens or their toxins to an organism. Antibodies produced through vaccines are a good example of adaptive immunity. Modern medicine is helping humans to build this kind of immunity.
– Then there is the innate immune response, which people are born with. Innate immunity is primitive and traces way back into the evolutionary process. It is less specific than adaptive immunity and generates a response to any pathogen rather than a specific bacteria or virus. Despite its primitive nature, innate immunity is a highly effective arm of the immune system. In fact, innate immunity is the reason for horseshoe crab survival over 250 million years.
– Innate immunity mediates its action via ancient protein families, such as pentraxins. Pentraxin-3, which is a key protein in the innate immune response, is rapidly secreted by many different cell types, and it recognizes conserved pathogen patterns and thus pathogens in general. Such mechanism resembles the function of antibodies in adaptive immunity, and, for this reason Pentraxin-3 is one that could be called an ancestor of antibodies. Apart from pathogen recognition, Pentraxin-3 also controls pathogen clearance and tissue repair, among other immune responses.
– It is a very exciting result for any drug candidate to trigger a protein like Pentraxin-3 with such a broad spectrum of effects.
Luiza, let me get this straight. Administration of Apta-1 induces Pentraxin-3 and Pentraxin-3 recognizes and could potentially be a strong force in killing pathogens, does that include viruses? And, in that case, do you see any potential effect of Apta-1 on viruses?
– It has only been a few days since the abstract was published but our team at Aptahem have, however, been discussing this topic over the past weeks given the COVID-19 virus outbreak as it’s an interesting and related area to sepsis.
– Based on our current knowledge of Apta-1 effects and the recent publications in these fields, we can say that it would be interesting to see if Apta-1 could have a direct or indirect potential against viruses given its multifunctional properties. But our plans right now is to continue to focus on the sepsis effects as our lead candidate Apta-1 is being developed as a treatment of sepsis.
– Sepsis has been reported to be a common complication in seriously affected virus patients. Thus, effective treatment against sepsis could potentially decrease mortality associated with a viral infection. Whether that would also include a virus like COVID-19 remains to be seen.
Finally, let’s return to sepsis, which is a critical, life-threatening condition where patients are very fragile. The seriousness of this condition probably means that regulatory authorities will require a very good safety and a favorable toxicity profile to approve new drugs for this indication. How do you reason around this in the plans for future studies in humans?
– This is outside my core competencies and Aptahem’s CMO Anders Bylock, our expert on these regulatory issues and clinical trials could better answer this question.
BioStock contacted Anders Bylock, CMO at Aptahem for a short comment:
– The toxicity profile of Apta-1 that we have seen this far does not indicate any major threats. It is correct that sepsis patients are in a fragile state and the unmet need is extremely high. Drugs targeting this condition must not worsen an already critical situation. However, as in all treatments used in highly threatening situations, some adverse effects could still be justified provided that the net effect is still positive.
– To give an example: a drug that improves parameters that are vitally important to a patient in the critical moment, such as prolongation of the time available for proper diagnosis, counteraction of organ damage/failure, need for extended critical care or even lowering of mortality could still have some adverse effects. Under those circumstances, usually non-acceptable side effects may become acceptable as long as the net balance is positive vs. the clinical benefit shown.
– I believe that if clinical results in patients treated with Apta-1 would reflect the results indicated in our animal experiments, these would likely support both approval and clinical use. Also, we are sure regulatory authorities would recognize the net value given the enormously high unmet clinical need in sepsis if the study result backs it up. The choice of patients in future studies will, of course, take fragility into account.
Innehållet i BioStocks nyheter och analyser är oberoende men BioStocks verksamhet är i viss mån finansierad av bolag i branschen. Detta inlägg avser ett bolag som BioStock erhållit finansiering från.
